Development of a novel anti-cancer agent, Sulforadex. Now in Phase I, it is initially being developed for prostate and breast cancer.
Evgen Limited is developing a novel cancer therapeutic called Sulforadex®, initially for early stage prostate cancer and prevention of recurrence of breast cancer. The product is in Phase I clinical trials. Sulforadex is a patented composition comprising a stabilised form of sulforaphane, a molecule that is well recognised for its therapeutic potential in a broad range of cancers but has hitherto been non-viable as a pharmaceutical.